

# Dementia - Pipeline Review, H1 2020

<https://marketpublishers.com/r/D6472E6FE19EN.html>

Date: February 2020

Pages: 469

Price: US\$ 2,000.00 (Single User License)

ID: D6472E6FE19EN

## Abstracts

Dementia - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H1 2020, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II, Phase I, Preclinical, Discovery and Unknown stages are 9, 24, 22, 54, 24 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 12 and 4 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Dementia - Overview

Dementia - Therapeutics Development

Dementia - Therapeutics Assessment

Dementia - Companies Involved in Therapeutics Development

Dementia - Drug Profiles

Dementia - Dormant Projects

Dementia - Discontinued Products

Dementia - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Dementia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Dementia - Pipeline by Acadia Pharmaceuticals Inc, H1 2020

Dementia - Pipeline by Actinogen Medical Ltd, H1 2020

Dementia - Pipeline by AcuraStem Inc, H1 2020

Dementia - Pipeline by Adamed Sp zoo, H1 2020

Dementia - Pipeline by ADEL Inc, H1 2020

Dementia - Pipeline by AgeneBio Inc, H1 2020

Dementia - Pipeline by Aibios Co Ltd, H1 2020

Dementia - Pipeline by Alector Inc, H1 2020

Dementia - Pipeline by Alkermes Plc, H1 2020

Dementia - Pipeline by Allergan Plc, H1 2020

Dementia - Pipeline by Alterity Therapeutics Ltd, H1 2020

Dementia - Pipeline by Anavex Life Sciences Corp, H1 2020  
Dementia - Pipeline by Annovis Bio Inc, H1 2020  
Dementia - Pipeline by Applied Genetic Technologies Corp, H1 2020  
Dementia - Pipeline by Aprinoia Therapeutics Inc, H1 2020  
Dementia - Pipeline by AriBio, H1 2020  
Dementia - Pipeline by Asceneuron SA, H1 2020  
Dementia - Pipeline by Axon Neuroscience SE, H1 2020  
Dementia - Pipeline by Axovant Gene Therapies Ltd, H1 2020  
Dementia - Pipeline by Axxome Therapeutics Inc, H1 2020  
Dementia - Pipeline by Biogen Inc, H1 2020  
Dementia - Pipeline by BioXcel Therapeutics Inc, H1 2020  
Dementia - Pipeline by Boehringer Ingelheim International GmbH, H1 2020  
Dementia - Pipeline by Bolder Biotechnology Inc, H1 2020  
Dementia - Pipeline by Cennerv Pharma (S) Pte Ltd, H1 2020  
Dementia - Pipeline by Cortice Biosciences Inc, H1 2020  
Dementia - Pipeline by CSPC NBP Pharmaceutical Co Ltd, H1 2020  
Dementia - Pipeline by Cyclarion Therapeutics Inc, H1 2020  
Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020  
Dementia - Pipeline by Denali Therapeutics Inc, H1 2020  
Dementia - Pipeline by DiaMedica Therapeutics Inc, H1 2020  
Dementia - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2020  
Dementia - Pipeline by Echo Pharmaceuticals BV, H1 2020  
Dementia - Pipeline by EIP Pharma LLC, H1 2020  
Dementia - Pipeline by Eisai Co Ltd, H1 2020  
Dementia - Pipeline by Eli Lilly and Co, H1 2020  
Dementia - Pipeline by Ensol Biosciences Inc, H1 2020  
Dementia - Pipeline by Enterin Inc, H1 2020  
Dementia - Pipeline by EVER Neuro Pharma GmbH, H1 2020  
Dementia - Pipeline by Galimedix Therapeutics Ltd, H1 2020  
Dementia - Pipeline by Gismo Therapeutics Inc, H1 2020  
Dementia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H1 2020  
Dementia - Pipeline by GW Pharmaceuticals Plc, H1 2020  
Dementia - Pipeline by HanAll Biopharma Co Ltd, H1 2020  
Dementia - Pipeline by Hemostemix Inc, H1 2020  
Dementia - Pipeline by HSRx Group, H1 2020  
Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2020  
Dementia - Pipeline by Immungenetics AG, H1 2020  
Dementia - Pipeline by ImStar Therapeutics Inc, H1 2020  
Dementia - Pipeline by Inhibikase Therapeutics Inc, H1 2020

Dementia - Pipeline by IntraBio Ltd, H1 2020  
Dementia - Pipeline by iQure Pharma Inc, H1 2020  
Dementia - Pipeline by IRLAB Therapeutics AB, H1 2020  
Dementia - Pipeline by Johnson & Johnson, H1 2020  
Dementia - Pipeline by Kogenix Therapeutics Inc, H1 2020  
Dementia - Pipeline by LA Cell Inc, H1 2020  
Dementia - Pipeline by Lachesis Biosciences Ltd, H1 2020  
Dementia - Pipeline by Luye Pharma Group Ltd, H1 2020  
Dementia - Pipeline by MediPost Co Ltd, H1 2020  
Dementia - Pipeline by Mediti Pharma Inc, H1 2020  
Dementia - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2020  
Dementia - Pipeline by MGC Pharmaceuticals Ltd, H1 2020  
Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2020  
Dementia - Pipeline by Neurimmune Holding AG, H1 2020  
Dementia - Pipeline by Neurodyn Cognition Inc, H1 2020  
Dementia - Pipeline by Neurokinine Therapeutics, H1 2020  
Dementia - Pipeline by NeuroScientific Biopharmaceuticals Ltd, H1 2020  
Dementia - Pipeline by NLS Pharma Group, H1 2020  
Dementia - Pipeline by Novartis AG, H1 2020  
Dementia - Pipeline by Oligomerix inc, H1 2020  
Dementia - Pipeline by Oryzon Genomics SA, H1 2020  
Dementia - Pipeline by Otsuka Holdings Co Ltd, H1 2020  
Dementia - Pipeline by P2D Inc, H1 2020  
Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H1 2020  
Dementia - Pipeline by Park Active Molecules, H1 2020  
Dementia - Pipeline by Passage Bio Inc, H1 2020  
Dementia - Pipeline by Plico Biotech Inc, H1 2020  
Dementia - Pipeline by Prevail Therapeutics Inc, H1 2020  
Dementia - Pipeline by ProMIS Neurosciences Inc, H1 2020  
Dementia - Pipeline by Prothena Corp Plc, H1 2020  
Dementia - Pipeline by Psy Therapeutics Inc, H1 2020  
Dementia - Pipeline by Resverlogix Corp, H1 2020  
Dementia - Pipeline by SanBio Inc, H1 2020  
Dementia - Pipeline by Sinfonia Biotherapeutics Inc, H1 2020  
Dementia - Pipeline by Stemedica Cell Technologies Inc, H1 2020  
Dementia - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020  
Dementia - Pipeline by Suven Life Sciences Ltd, H1 2020  
Dementia - Pipeline by SyneuRx International Corp, H1 2020  
Dementia - Pipeline by T3D Therapeutics Inc, H1 2020

Dementia - Pipeline by TauRx Therapeutics Ltd, H1 2020  
Dementia - Pipeline by Theranexus SAS, H1 2020  
Dementia - Pipeline by UniQure NV, H1 2020  
Dementia - Pipeline by Voyager Therapeutics Inc, H1 2020  
Dementia - Pipeline by Wave Life Sciences Ltd, H1 2020  
Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2020  
Dementia - Dormant Projects, H1 2020  
Dementia - Dormant Projects, H1 2020 (Contd..1), H1 2020  
Dementia - Dormant Projects, H1 2020 (Contd..2), H1 2020  
Dementia - Dormant Projects, H1 2020 (Contd..3), H1 2020  
Dementia - Dormant Projects, H1 2020 (Contd..4), H1 2020  
Dementia - Dormant Projects, H1 2020 (Contd..5), H1 2020  
Dementia - Discontinued Products, H1 2020  
Dementia - Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Dementia, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Acadia Pharmaceuticals Inc  
Actinogen Medical Ltd  
AcuraStem Inc  
Adamed Sp zoo  
ADEL Inc  
AgeneBio Inc  
Aibios Co Ltd  
Alector Inc  
Alkermes Plc  
Allergan Plc  
Alterity Therapeutics Ltd  
Anavex Life Sciences Corp  
Annovis Bio Inc  
Applied Genetic Technologies Corp  
Aprinoia Therapeutics Inc  
AriBio  
Asceneuron SA  
Axon Neuroscience SE  
Axovant Gene Therapies Ltd  
Axsome Therapeutics Inc  
Biogen Inc

BioXcel Therapeutics Inc  
Boehringer Ingelheim International GmbH  
Bolder Biotechnology Inc  
Cennerv Pharma (S) Pte Ltd  
Cortice Biosciences Inc  
CSPC NBP Pharmaceutical Co Ltd  
Cyclerion Therapeutics Inc  
Daewoong Pharmaceutical Co Ltd  
Denali Therapeutics Inc  
DiaMedica Therapeutics Inc  
Dr. August Wolff GmbH & Co KG Arzneimittel  
Echo Pharmaceuticals BV  
EIP Pharma LLC  
Eisai Co Ltd  
Eli Lilly and Co  
Ensol Biosciences Inc  
Enterin Inc  
EVER Neuro Pharma GmbH  
Galimedix Therapeutics Ltd  
Gismo Therapeutics Inc  
Guangzhou Magpie Pharmaceutical Co Ltd  
GW Pharmaceuticals Plc  
HanAll Biopharma Co Ltd  
Hemostemix Inc  
HSRx Group  
Hyundai Pharmaceutical Co Ltd  
Immungenetics AG  
ImStar Therapeutics Inc  
Inhibikase Therapeutics Inc  
IntraBio Ltd  
iQure Pharma Inc  
IRLAB Therapeutics AB  
Johnson & Johnson  
Kogenix Therapeutics Inc  
LA Cell Inc  
Lachesis Biosciences Ltd  
Luye Pharma Group Ltd  
MediPost Co Ltd  
Mediti Pharma Inc

Merz Pharma GmbH & Co KgaA  
MGC Pharmaceuticals Ltd  
Neuraltus Pharmaceuticals Inc  
Neurimmune Holding AG  
Neurodyn Cognition Inc  
Neurokine Therapeutics  
NeuroScientific Biopharmaceuticals Ltd  
NLS Pharma Group  
Novartis AG  
Oligomerix inc  
Oryzon Genomics SA  
Otsuka Holdings Co Ltd  
P2D Inc  
Pacific Northwest Biotechnology LLC  
Park Active Molecules  
Passage Bio Inc  
Plico Biotech Inc  
Prevail Therapeutics Inc  
ProMIS Neurosciences Inc  
Prothena Corp Plc  
Psy Therapeutics Inc  
Resverlogix Corp  
SanBio Inc  
Sinfonia Biotherapeutics Inc  
Stemedica Cell Technologies Inc  
Sun Pharma Advanced Research Company Ltd  
Suven Life Sciences Ltd  
SyneuRx International Corp  
T3D Therapeutics Inc  
TauRx Therapeutics Ltd  
Theranexus SAS  
UniQure NV  
Voyager Therapeutics Inc  
Wave Life Sciences Ltd  
WhanIn Pharmaceutical Co Ltd

## I would like to order

Product name: Dementia - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/D6472E6FE19EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D6472E6FE19EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970